Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1165-1175

  Pizzorno, Giuseppe ^a   Yee, Lorrin ^b   Burtness, Barbara A ^a   Marsh, John C ^a   Darnowski, James W ^c   Chu, Ming Yu W ^c   Chu, Shih Hsi ^c   Chu, Edward ^b   Leffert, Janine J ^a   Handschumacher, Robert E ^a   Calabresi, Paul ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b West Haven   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; BENZYLACYCLOURIDINE; FLUOROURACIL; IND 039655; UNCLASSIFIED DRUG; URIDINE; URIDINE PHOSPHORYLASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FATIGUE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SWINE;

AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SWINE; TISSUE DISTRIBUTION; URACIL; URIDINE PHOSPHORYLASE;

EID: 15644382548     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Krenisky, T. A., Barclay, M., and Jacquez, J. A. Specificity of mouse uridine phosphorylase. Chromatography, purification and properties. J. Biol. Chem., 239: 805-812, 1964.
2. Krenisky, T. A., Mellors, J. W., and Barclay, R. K. Pyrimidine nucleosidases, their classification and relationship to uric acid ribonucleoside phosphorylase. J. Biol. Chem., 240: 1281-1286, 1965.
3. Niedzwicki, J. G., El Kouni, M. D., Chu, S. H., and Cha, S. Pyrimidine acyclonucleosides inhibitors of uridine phosphorylase. Biochem. Pharmacol., 30: 2097-2101, 1981.
4. Niedzwicki, J. G., Chu, S. H., El Kouni, M. H., Rowe, E. C., and Cha, S. 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine posphorylase. Biochem. Pharmacol., 31: 1857-1861, 1982.
5. Pontis, H., Degerstedt, G., and Reichard, P. Uridine and deoxyuridine phosphorylase from Ehrlich ascites tumor. Biochim. Biophys. Acta, 51: 138-147, 1961.
6. Liu, M. P., Srimatkandada, S., Handschumacher, R. E., and Pizzorno, G. Variant uridine phosphorolytic activity in human breast and head-neck tumors: a potential target for improving 5-FU therapy. Proc. Am. Assoc. Cancer Res., 37: 2786, 1996.
7. Darnowski, J. W., and Handschumacher, R. E. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res., 45: 5364-5368, 1985.
8. Chu, S. Y., Weng, Z. Y., Chen, Z. H., Rowe, E. C., Chu, E., Naguib, F. N. M., el Kouni, M. H., Cha, S., and Chu, M. Y. Synthesis of 5-benzyl and 5-benzyloxybenzyl 2,2′-anhydrouridines and related nucleoside analogs as inhibitors of uridine phosphorylase. Nucleosides Nucleotides, 7: 91-102, 1988.
9. Monks, A., Ayers, O., and Cysyk, R. L. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem. Pharmacol., 32: 2003-2009, 1983.
10. Martin, D. S., Stolfi, R. L., and Sawyer, R. C. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother. Pharmacol., 24: 9-14, 1989.
11. Mukherjee, K. L., Boohar, J., Wentland, D., Ansfield, F. J., and Heidelberger, C. Studies on fluorinated pyrimidines. XVI. Metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine-2-C14 in cancer patients. Cancer Res., 23: 49-66, 1963.
12. Birnie, G. D., Kroeger, H., and Heidelberger, C. Studies of fluorinated pyrimidines. XVIII. The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucieoside phosphorylase. Biochemistry, 2: 566-572, 1963.
13. Darnowski, J. W., Holdridge, C., and Handschumacher, R. E. Concentrative uridine transport by murine splenocytes: kinetics, substrate specificity and sodium dependency. Cancer Res., 47: 2614-2619, 1987.
14. Leyva. A., Van Groeningen, C. J., Leyva, A., Kraal, I., Peters, G. J., Lankelma, J., and Pinedo, H. M. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res., 44: 5928-5933, 1984.
15. Van Groeningen, C. J., Leyva, A., Kraal, I., Peters, G. J., and Pinedo, H. M. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat. Rep., 70: 745-750, 1986.
16. Seiter, K., Kemeny, N., Martin, D., Schneider, A., Williams, L., Colofiore, J., and Sawyer, R. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. Cancer (Phila.), 71: 1875-1881, 1993.
17. Kelsen, D. P., Martin, D., O'Neil, J., Schwartz, G., Saltz, L., Sung, M. T., von Borstel, R., and Bertino, J. R. Phase I clinical trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J. Clin. Oncol., 15: 1511-1517, 1997.
18. Chu, M. W., Naguib, F. N, Itzsch, M. H., El Kouni, M. D., Chu, S. H., and Calabresi, P. Potentiation of 5-fluoro-2′-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine. Cancer Res. 44: 1852-1856, 1984.
19. Darnowski, J. W., and Handschumacher, R. E. Tissue uridine pools evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res., 46: 3490-3494, 1986.
20. Darnowski, J. W., and Handschumacher, R. E., Benzylacyclouridine pharmacokinetics, metabolism and biochemical effect in mice. Biochem. Pharmacol., 37: 2613-2619, 1988.
21. Yee, L., Chu, M. Y. W., Pan, B. C., Chu, S. H., and Calabresi, P. Correlation of uridine phosphorylase inhibition with enhancement of 5-fluorouracil anticancer activity by benzylacyclouridine (BAU) in human prostate carcinoma cell lines. Proc. Am. Assoc. Cancer Res., 37: 409, 1996.
22. Holland, S. K., Bergman, A. M., Zhao, Y. M., Adams, E. R., and Pizzorno, G. 19F-NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine. Magn. Reson. Med., 38: 907-916, 1997.
23. Calabresi, P., Falcone, A., St. Clair, M. H., Wiemann, M. C., Chu, S. H., and Darnowski, J. W. Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity. Blood, 76: 221-2215, 1990.
24. Sommadossi, J. P., Carlisle, R., Schinazi, R. F., and Zhou, Z. Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob. Agents Chemother., 32: 997-1001, 1988.
25. Davis, S. T., Joyner, S. S., Chandrasurin, P., and Baccanari, P. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine. Biochem. Pharmacol., 45: 173-181, 1993.
26. Sommadossi, J-P., Cretton, E. M., Kidd, L. B., McClure, H. M., Anderson, D. C., and el Kouni, M. H. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys. Cancer Chemother. Pharmacol., 37: 14-22, 1995.
27. Peters, G. L., van Groeningen, C. J., Laurensse, E., Kraal, I., Leyva, A., Lankelma, J., and Pinedo, H. M. Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. Pharm. (N. Y.) Res., 4: 113-119, 1987.
28. Sommadossi, J-P., and el Kouni, M. H. Modulation of uridine pharmacokinetics in rhesus monkeys by dilazep (abstract). Proc. Am. Assoc. Cancer Res., 35: 319, 1994.
29. Naguib, F. N. M., Soong, S-J., and el Kouni, M. H. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases, and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem. Pharmacol., 45: 667-674, 1993.
30. el Kouni, M. H., Naguib, F. N., Park, K. S., Cha, S., Darnowski, J. W., and Soong, S. J. Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem. Pharmacol., 40: 2479-2485, 1990.